Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
2008
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
publication
Evidence: moderate
Author Information
Author(s): Michelakis E D, Webster L, Mackey J R
Primary Institution: University of Alberta
Hypothesis
Can dichloroacetate (DCA) effectively reverse the metabolic remodeling in cancer cells to promote apoptosis?
Conclusion
DCA can reverse the resistance to apoptosis in cancer cells and suppress tumor growth both in vitro and in vivo.
Supporting Evidence
- DCA has been shown to induce apoptosis in various cancer cell lines.
- DCA reverses the metabolic remodeling in cancer cells, promoting glucose oxidation.
- Preclinical studies indicate that DCA can suppress tumor growth in animal models.
Takeaway
DCA is a drug that helps cancer cells die by changing how they use energy, which can stop tumors from growing.
Methodology
The review discusses the effects of DCA on cancer cell metabolism and its potential as a therapeutic agent based on preclinical studies.
Limitations
The review highlights the need for clinical trials to confirm DCA's efficacy and safety in cancer treatment.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website